<DOC>
	<DOCNO>NCT01096225</DOCNO>
	<brief_summary>The primary immunogenicity objective ass antibody response T-cell response split-virion inactivate A ( H1N1 ) vaccine . Participants include 20 healthy person age 20 old history novel influenza H1N1 2009 infection late 3 month novel influenza H1N1 2009 vaccination . This randomized study healthy male non-pregnant female , age 20 year old . All subject stratify 1 dose group ( 15mcg per dose ) , receive intramuscular influenza H1N1 vaccine . The H1N1 vaccine administer Day 0 Day 21 . On Day 0 , Day 10 , Day 21 , Day 28 , Day 35 Day 42 first vaccination ( Day 0 ) , immunogenicity test manipulate . The antibody response immunogenicity test hemagglutination inhibiting ( HAI ) serum . The T-cell response interferon-gamma ELISPOT assay Tetramer stain use PBMCs .</brief_summary>
	<brief_title>Immunogenicity Study S-OIV H1N1 Influenza Vaccine</brief_title>
	<detailed_description>In 2009 , novel swine-origin influenza A/H1N1 virus identify significant cause febrile respiratory illness North America . It rapidly spread many country around world , soon meet World Health Organization ( WHO ) criteria pandemic . Data several clinical trail split-virion inactivated S-OIV vaccine suggest vaccine stimulate strong specific antibody S-OIV . However , T-cell response data vaccination . In addition , know S-OIV specific cellular immunity level population . These fact indicate need ass antibody response T-cell response vaccination split-virion inactivate S-OIV vaccine . The primary immunogenicity objective ass antibody response T-cell response split-virion inactivate A ( H1N1 ) vaccine . Participants contain one age group , include 20 healthy person age 20 old history novel influenza H1N1 2009 infection late 3 month novel influenza H1N1 2009 vaccination . This randomized study healthy male non-pregnant female . All subject stratify 1 dose group ( 15mcg per dose ) , receive intramuscular influenza H1N1 vaccine . The H1N1 vaccine administer Day 0 Day 21 . On Day 0 , Day 10 , Day 21 , Day 28 , Day 35 Day 42 first vaccination ( Day 0 ) , immunogenicity test manipulate . The antibody response immunogenicity test hemagglutination inhibiting ( HAI ) serum . The T-cell response interferon-gamma ELISPOT assay Tetramer stain use PBMCs .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Healthy male female age 20 old 2 . Be able show legal identity card sake recruitment 3 . Volunteers guardian able understand sign inform consent 1 . Cases , cure case close contact influenza A ( H1N1 ) virus 2 . Women pregnancy , lactation pregnant 60 day 3 . Subject medical history following : allergic history , allergic ingredient vaccine , egg , egg protein , etc 4 . Serious adverse reaction vaccine anaphylaxis , hive , respiratory difficulty , angioedema , abdominal pain 5 . Autoimmune disease immunodeficiency 6 . Asthma unstable require emergent care , hospitalization intubation past two year require use oral intravenous corticosteroid 7 . Diabetes mellitus ( type I II ) , exception gestational diabetes 8 . History thyroidectomy thyroid disease require medication within past 12 month 9 . Serious angioedema episode within previous 3 year require medication previous two year 10 . Bleeding disorder diagnose doctor ( e.g . factor deficiency , coagulopathy , platelet disorder require special precaution ) significant bruise bleed difficulty IM injection blood draws 11 . Active malignancy treat malignancy reasonable assurance sustain cure malignancy likely recur period study 12 . Seizure disorder : Febrile seizure age two year old Seizures secondary alcohol withdrawal 3 year ago , A singular seizure require treatment within last 3 year 13 . Asplenia , functional asplenia condition result absence removal spleen 14 . GuillainBarre Syndrome 15 . Any history immunosuppressive medication cytotoxic medication inhale corticosteroid within past six month ( exception corticosteroid nasal spray allergic rhinitis topical corticosteroid acute uncomplicated dermatitis ) 16 . History blood product swineorigin H1N1 seasonal influenza vaccine administration within 3 month dose 17 . Administration investigational research agent within 30 day dose 18 . Administration live attenuate vaccine within 30 day dose 19 . Administration subunit inactivate vaccine , e.g. , pneumococcal vaccine , allergy treatment antigen injection , within 14 day dose 20 . Be receive antiTB prophylaxis therapy currently 21 . Axillary temperature &gt; 37.0 centigrade time dose 22 . Psychiatric condition precludes compliance protocol : Past present psychosis Past present bipolar disorder require therapy well control medication past two year Disorder require lithium Suicidal ideation occur within five year prior enrollment 23 . Any medical , psychiatric , social condition , occupational reason responsibility , judgment investigator , contraindication protocol participation impair volunteer 's ability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>antibody response</keyword>
	<keyword>T-cell response</keyword>
	<keyword>S-OIV</keyword>
	<keyword>vaccine</keyword>
	<keyword>Immunogenicity assessment</keyword>
</DOC>